Key facts
- This page summarizes Brian Hullinger's Form 4 filing for PSYCHEMEDICS CORP (PMDI).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 21 Aug 2023, 17:48.
Brian Hullinger - 17 Aug 2023 Form 4 Insider Report for PSYCHEMEDICS CORP (PMDI)
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- PMDI
- Reported as of
- 17 Aug 2023
- Net transaction value
- $0
- Reporting owner signature
- Patrick J. Kinney, Jr. as attorney-in-fact for Brian Hullinger
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Brian Hullinger filed Form 4 for PSYCHEMEDICS CORP (PMDI) on 21 Aug 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PMD
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- Price
- $0.000000
- Shares after
- 100,000
- Date
- 17 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock, $.005 Par Value
- Underlying amount
- 100,000
- Exercise price
- $4.64
- Footnotes
- F1
PMD
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +200,000
- Change %
- Price
- $0.000000
- Shares after
- 200,000
- Date
- 17 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock, $.005 Par Value
- Underlying amount
- 200,000
- Exercise price
- $4.64
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option becomes exercisable with respect to 50% of the shares on August 17, 2024 and with respect to the remaining 50% on August 17, 2025.
Footnote F2
The option becomes exercisable, if at all, in two 100,000 share increments if the weighted average daily price of Psychemedics Corporation's common stock on the Nasdaq Stock Market during any 60 consecutive calendar day period exceeds $5.50 and $6.50, respectively.